Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about

< Previous 1 2 3 4 5 Next >
Cytori Therapeutics Reminds Investors of Today’s Deadline to be a Shareholder of Record
Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the “Company”) today issued a reminder to shareholders that the Record Date of its proposed rights offering is June 26, 2018. To be a shareholder of... 
From GlobeNewswire News Releases
40 Biggest Movers From Yesterday
Gainers AGM Group Holdings Inc. (NASDAQ: AGMH) shares jumped 71.39 percent to close at $27.80 on Thursday. Destination Maternity ... 
Tags SEII BMA CYTX
From Benzinga
The Stem Cell Market is Projected to Grow Due to Technological Advancements
FinancialBuzz.com News Commentary 
From PR Newswire
Benzinga's Weekly Movers For The Week Of May 25, 2018
Benzinga’s Weekly Movers For The Week Of May 25, 2018 The data presented below was compiled using a Screener widget and ... 
Tags REPH CYTX ACHV
From Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cytori Therapeutics, Inc.
Levi & Korsinsky announces it has commenced an investigation of Cytori Therapeutics, Inc. 
From Business Wire News Releases
Cytori Reports Q1 2018 Business and Financial Results
Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced Q1 2018 financial results and provided updates on corporate development. 
From GlobeNewswire News Releases
Cytori to Webcast First Quarter Financial Results on May 10
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 10, 2018 at 5:30 PM Eastern Time. 
From GlobeNewswire News Releases
Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin
Cytori Therapeutics, Inc. (Nasdaq:CYTX) (“Cytori” or “the Company”) today provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product. ATI-0918... 
From GlobeNewswire News Releases
Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy™ for Stress Urinary Incontinence
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that full enrollment has been reached in the ADRESU investigator-initiated clinical trial of Cytori Cell Therapy™ for men with stress urinary... 
From GlobeNewswire News Releases
BRIEF-Cytori Therapeutics - Co Met With U.S. FDA To Discuss Outcome Of Star Clinical Trial
* CYTORI THERAPEUTICS - ON MARCH 1, CO MET WITH U.S. FDA TO DISCUSS OUTCOME OF STAR CLINICAL TRIAL AND CO'S PLANS FOR HABEO CELL THERAPY - SEC FILING 
Tags companyNews
From Reuters: Company News
Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results
Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced its fourth quarter and year-end 2017 financial results and provided updates on its corporate activity and clinical... 
From GlobeNewswire News Releases
Cytori Therapeutics Q4 Earnings Preview
On Thursday, Cytori Therapeutics (NASDAQ: CYTX) will release its latest earnings report. Here is Benzinga's outlook for the ... 
Tags Benzinga Earnings Previews
From Benzinga
Cytori to Webcast Fourth Quarter Financial Results on March 8th
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its fourth quarter financial results and business update on Thursday, March 8, 2018 at 5:30 PM Eastern Time. 
From GlobeNewswire News Releases
Cytori Scleroderma Trial Data Presented at Systemic Sclerosis World Congress
Cytori Therapeutics, Inc. (Nasdaq:CYTX) (“Cytori” or “the Company”) today presented data from the U.S. 88 patient, 19 center, randomized, double blind, placebo-controlled STAR clinical trial of Cytori... 
From GlobeNewswire News Releases
Cytori Therapeutics Announces Inducement Grants for New Employees
Cytori Therapeutics, Inc. (NASDAQ:CYTX) (the “Company”), announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on January 25, 2018 to... 
From GlobeNewswire News Releases
BRIEF-Cytori Therapeutics Says David Rickey And Gail Naughton Submitted Resignations As Members Of Board
* CYTORI THERAPEUTICS - ON JAN 25, AS PART OF ONGOING RESTRUCTURING DAVID M. RICKEY AND GAIL K. NAUGHTON, SUBMITTED RESIGNATIONS AS MEMBERS OF BOARD 
Tags companyNews
From Reuters: Company News
Enrollment Completed in Randomized Clinical Trial of Habeo™ Cell Therapy for Scleroderma and Impaired Hand Function
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces completion of patient enrollment in SCLERADEC II (NCT02558543), a randomized, double-blind, placebo-controlled, parallel group, multi-center clinical... 
From GlobeNewswire News Releases
BRIEF-Swissquote Bank Sells 188,426 Shares Of Cytori Therapeutics Inc's Common Stock Between Jan 9-11
* SWISSQUOTE BANK SA REPORTS OPEN MARKET SALE OF 188,426 SHARES OF CYTORI THERAPEUTICS INC'S COMMON STOCK BETWEEN JAN 9 AND JAN 11 - SEC FILING Source text: (http://bit.ly/2ExdrAg) Further company... 
Tags companyNews
From Reuters: Company News
BRIEF-Swissquote Bank SA Reports 12 pct Passive Stake In Cytori Therapeutics As Of Dec. 29, 2017
* SWISSQUOTE BANK SA REPORTS 12 PERCENT PASSIVE STAKE IN CYTORI THERAPEUTICS INC AS OF DECEMBER 29, 2017 - SEC FILING?? Source text - (http://bit.ly/2CUutMr) Further company coverage: 
Tags companyNews
From Reuters: Company News
Cytori Closes Rights Offering for Gross Proceeds of $10 Million
Cytori Therapeutics, Inc. (“Cytori”) (NASDAQ:CYTX) announced today the closing of its rights offering (the “Rights Offering”) to subscribe for units at a subscription price of $1,000 per unit. 
From GlobeNewswire News Releases
Cytori Announces Expiration of Oversubscribed Rights Offering
Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), announced today that the subscription period for its previously announced rights offering (the “Offering”) of units at a... 
From GlobeNewswire News Releases
Cytori Reports Reduction in Fibrosis Parameters in Scar Study
BARDA Funded Preclinical Published in Stem Cell Research and Therapy 
From GlobeNewswire News Releases
Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS
Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced the results of its pharmacokinetic bioequivalence trial of ATI-0918 (test product) and European sourced CAELYX® (reference... 
From GlobeNewswire News Releases
Cytori Reminds Stockholders That Rights Offering Expires on Tuesday, November 21
Cytori Therapeutics, Inc. (Nasdaq:CYTX) provides a reminder to stockholders that its previously announced rights offering will remain open until 5:00 PM Eastern Time on Tuesday, November 21, 2017.... 
From GlobeNewswire News Releases
Cytori Announces New U.S. Investigator Trial for Hip Osteonecrosis
Updates on Other Selected Global Investigator Initiated Trials 
From GlobeNewswire News Releases
Cytori Reports Third Quarter 2017 Business and Financial Results
Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced its third quarter 2017 financial results and provided updates on its corporate activity and clinical development. 
From GlobeNewswire News Releases
STAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress
Cytori Therapeutics, Inc. (Nasdaq:CYTX) (“Cytori” or “the Company”) announced today that its U.S. STAR clinical trial assessing the safety and efficacy of Habeo™ Cell Therapy for hand dysfunction due... 
From GlobeNewswire News Releases
Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, Marinus Pharma, and NewLink Genetics
If you want a Stock Review on CYTX, SRNE, MRNS, or NLNK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com observes... 
From PR Newswire
Cytori to Webcast Third Quarter Financial Results on November 9
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its third quarter financial results and business update on Thursday, November 9, 2017 at 5:30 PM Eastern Time. 
From GlobeNewswire News Releases
Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics
From PR Newswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.